Literature DB >> 15492115

Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma.

Sun Yang1, Frank L Meyskens.   

Abstract

Resveratrol has demonstrated preventive and therapeutic activities in a variety of tumors. However, the mechanistic basis of its pharmacological effects on human melanoma has not been well defined. Our results demonstrated that resveratrol significantly inhibited melanoma anchorage-independent growth, and even at high doses no distinct apoptosis or cell cycle arrest was observed. It is noteworthy that c83-2c (metastatic) and wm3211 (radial growth phase) melanoma cells became more dendritic shaped with resveratrol treatment. Major histocompatibility complex (MHC) class I antigen and Fas/CD95 constitutive surface expression levels were, respectively, increased by 2.7- and 1.6-fold of control in c83-2c cells. Resveratrol reduced both activator protein-1 (AP-1) DNA binding and transcriptional activities, and supershift assay revealed that AP-1 composition was shifted from c-Jun/JunD/Fra-1 to JunD/Fra-1/Fra-2, with markedly increased JunD, Fra-1, and Fra-2 protein expression levels in the nucleus. Furthermore, we overexpressed Fra-2 in human melanoma cells by using a Fra-2 expression construct and both AP-1 transcriptional activity and 12-O-tetradecanoylphorbol-induced transcriptional transactivation were reduced significantly, whereas MHC class I antigen and Fas/CD95 levels were elevated to 2.0 and 1.8 times of control, respectively. Addition of H(2)O(2) (10 muM) partially reversed the inhibition of colony proliferation; however, no effects on either MHC class I antigen or Fas expression was evident. Although H(2)O(2) restored participation of c-Jun in AP-1 complexes, H(2)O(2) addition did not affect the induction of Fra-1 and Fra-2 by resveratrol nor the morphological changes. We propose that alterations in AP-1 transcription signaling, mediated by changes in AP-1 dimeric composition and reduced intracellular reactive oxygen species levels, substantially contribute to the phenotypic changes induced by resveratrol.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492115     DOI: 10.1124/mol.104.006023

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Effect of ultraviolet B radiation on activator protein 1 constituent proteins and modulation by dietary energy restriction in SKH-1 mouse skin.

Authors:  Brian D Hopper; Joseph Przybyszewski; Haw-Wen Chen; Kimberly D P Hammer; Diane F Birt
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

2.  Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth.

Authors:  Richard M Niles; Carla P Cook; Gary G Meadows; Ya-Min Fu; Jerry L McLaughlin; Gary O Rankin
Journal:  J Nutr       Date:  2006-10       Impact factor: 4.798

3.  Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Authors:  Brenda L Soto; Jacquelyn A Hank; Soesiawati R Darjatmoko; Arthur S Polans; Eric M Yanke; Alexander L Rakhmilevich; Songwon Seo; KyungMann Kim; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Int Immunopharmacol       Date:  2011-08-18       Impact factor: 4.932

Review 4.  Botanicals for the prevention and treatment of cutaneous melanoma.

Authors:  Deeba N Syed; Hasan Mukhtar
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-12       Impact factor: 4.693

Review 5.  The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.

Authors:  Mary Ndiaye; Carol Philippe; Hasan Mukhtar; Nihal Ahmad
Journal:  Arch Biochem Biophys       Date:  2011-01-04       Impact factor: 4.013

6.  Common and distinct mechanisms of different redox-active carcinogens involved in the transformation of mouse JB6P+ cells.

Authors:  Sun Yang; Bobbye Misner; Rita Chiu; Frank L Meyskens
Journal:  Mol Carcinog       Date:  2008-07       Impact factor: 4.784

7.  Substituted trans-stilbenes can inhibit or enhance the TPA-induced up-regulation of activator protein-1.

Authors:  Lorraine M Deck; Lucy A Hunsaker; Amanda M Gonzales; Robert A Orlando; David L Vander Jagt
Journal:  BMC Pharmacol       Date:  2008-11-10

8.  Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Authors:  Ryan W Dellinger; Harry H Matundan; Amelia S Ahmed; Priscilla H Duong; Frank L Meyskens
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

9.  HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.

Authors:  Weiwen He; Yanna Wu; Xiaomei Tang; Yong Xia; Guozhen He; Zhiqun Min; Chun Li; Shiqiu Xiong; Zhi Shi; Yongjian Lu; Zhongmin Yuan
Journal:  Oncotarget       Date:  2016-02-09

10.  The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression.

Authors:  Zhen Yang; Sun Yang; Bobbye J Misner; Feng Liu-Smith; Frank L Meyskens
Journal:  Int J Oncol       Date:  2014-08-08       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.